DNA topoisomerase I inhibitor. Exhibits a different inhibitory mechanism to camptothecin
(Cat. No. 1100). Induces apoptosis in a variety of cell lines, including prostate cancer and promyelocytic leukemia cells; blocks the cell cycle in G0
. Also has effects on DNA topoisomerase II, NF-κ
B, AP-1, and JNK.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Suppression of tumor necrosis factor-activated nuclear transcription factor-κB, activator protein-1, c-Jun N-terminal kinase, and apoptosis by β lapachone.
Manna et al.
Beta-Lapachone, a novel topoisomerase I inhibitor with a mode of action different from camptothecin.
Li et al.
Activation of c-Jun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor β-lapachone-induced apoptosis through an oxidation-dependent pathway
Shiah et al.
Cancer Res., 1999;59:391
Induction of apoptosis in MCF-7:WS8 breast cancer cells by β-Lapachone.
Wuerzberger et al.
Cancer Res., 1998;58:1876